Top Stories
The Chinese firm is developing radiopharmaceutical assets targeting oncology and neurological disorders, several of which are lined up for IND submissions.
The spin-off from Addex Therapeutics is developing NTX-253, an oral muscarinic M4 positive allosteric modulator, for schizophrenia.
The Dutch biotech's lead programme is VTx-002, a first-in-class vectorised antibody targeting TDP-43 pathology in people with amyotrophic lateral sclerosis (ALS).
The oral inhibitor delivered a roughly 30-percentage-point placebo-adjusted benefit on the primary endpoint at week 48.
Both dosing regimens of the CD40L antagonist fusion protein dazodalibep reduced systemic disease activity compared to placebo.
Conference News
According to Fidelity, RBC Capital Markets said Legend Biotech’s Carvykti is positioned to sustain growth into 2027, potentially supporting profitability and margin expansion.Indicated for multiple my...
SHANGHAI and HONG KONG, Nov. 11, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discoveri...
SHANGHAI, Nov. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced that LAE124, its internally discovered novel oral small-molecule dual Amylin/Calcitonin receptor agonist (DACRA) for the treatment of...
FirstWord will be speaking with a leading expert about detailed Phase II data for Beeline's afimetoran, and what they suggest about the prospects for TLR7/8 inhibitors in lupus.
Pelareorep and toripalimab combine potentially complementary mechanisms designed to enhance antitumor immune responses and help overcome tumor immune resistanceStudy may represent a first step toward ...
